Hinova Pharmaceuticals (SHSE:688302) Total Liabilities : ¥146.19 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Hinova Pharmaceuticals Total Liabilities?

Hinova Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2025 was ¥146.19 Mil.

Hinova Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2024 (¥173.17 Mil) to Dec. 2024 (¥169.34 Mil) and declined from Dec. 2024 (¥169.34 Mil) to Mar. 2025 (¥146.19 Mil).

Hinova Pharmaceuticals's annual Total Liabilities declined from Dec. 2022 (¥149.68 Mil) to Dec. 2023 (¥124.48 Mil) but then increased from Dec. 2023 (¥124.48 Mil) to Dec. 2024 (¥169.34 Mil).

Hinova Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Hinova Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hinova Pharmaceuticals Total Liabilities Chart

Hinova Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

202.33

193.59

149.68

124.48

169.34

Hinova Pharmaceuticals Quarterly Data
	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															108.34	166.05	173.17	169.34	146.19

Hinova Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Hinova Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	146.954	+	(5.831	+	16.55
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	169.34

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	1361.58	-	1192.245
	=	169.34

Hinova Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	124.552	+	(5.092	+	16.55
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	146.19

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	1309.873	-	1163.679
	=	146.19

Hinova Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Hinova Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Hinova Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hinova Pharmaceuticals Inc (SHSE:688302) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041

Website

http://www.hinovapharma.com

Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.

Hinova Pharmaceuticals Headlines

No Headlines